• For Institutions

    • Corporate Services
    • Developers
  • Download
  • Help
  • About

    • Company Profile
    • License & Regulatory
    • Media coverage
longbridgelongbridge
longbridgelongbridge
Products
Pricing
Markets
Global Markets
Stock Screener
Information
Insights
News
Live
Academy
Affiliate Program
Promotions
PortAI
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
News
Holdings
Company Encyclopedia
View More
name
PP CN NEWECON-U
09173.HK
Shareholder
Ownership%OwnedShare ChgReport Date
No Data
News
View More

CATL Makes Big Announcement on Sodium Batteries for 2026

CATL, the world's largest battery producer, announced significant developments in sodium-ion batteries for 2026, highlighting their potential for passenger electric vehicles with a range of 500 km. The company emphasizes a dual-market approach, integrating both sodium and lithium batteries, with sodium-ion technology expected to offer cost savings, safety benefits, and performance in extreme temperatures. This announcement marks a shift from research to market focus for sodium-ion batteries, indicating a promising future in various industry segments, including EVs and energy storage systems.

cleantechnica·Yesterday at 16:41
HK
03750
+1.19%
SZ
300750
+0.58%
cleantechnica·Yesterday at 16:41
HK
03750
+1.19%
SZ
300750
+0.58%
© 2025 Longbridge|Disclaimer

Schedules & Filings

Schedules
Filings
Aug5
Distribution Plan(CST)

Cash dividend 0.0988

Jul31
Distribution Plan(CST)

Cash dividend 0.0988

Jul30
Distribution Plan(CST)

Cash dividend 0.0988

View More

Event Tracking

Dec31
ZTE Chairman Fang Rong Outlines 2026 Corporate Strategy
01:26
BOMP TIMES Commences 450,000 Tons/Year New Generation Lithium Iron Phosphate Project
01:14
Dec30
CATL Exceeds Annual Switch Station Targets and Plans Future Expansion
14:05
ZTE Exceeds 100 Million Home Terminal Shipments in 2025, Maintains Top Global Market Share for 5 Consecutive Years
08:23
Times Qiji New Energy Technology Co., Ltd Established with a Registered Capital of 5 Million Yuan
02:27
Dec29
Hengrui Medicine Subsidiary Obtains Clinical Trial Approval for HRS-6257
10:01